Regeneron has launched a consortium to fund the generation of genetic exome sequence data from 500,000 volunteer participants, the company announced in a press release.
The “precompetitive” consortium includes collaborators AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen and Pfizer, which will each commit $10 million to enable the acceleration of sequencing timelines, while Regeneron conducts the sequencing effort, according to the release.
Volunteer participants from the UK Biobank health resource will be sequenced with detailed, de-identified medical and health records
Uncategorized